---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-036870"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:23:14.442516+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theravance settles YUPELRI patent suit; generic license start April 23, 2039

## Summary
- Settlement with Mankind Pharma resolves Hatch-Waxman litigation over YUPELRI (revefenacin) ANDA.
- Royalty-free license granted for generic version on or after April 23, 2039, subject to customary exceptions.
- All pending Hatch-Waxman litigation relating to YUPELRI now resolved; settlement subject to DOJ/FTC review.
- Involves patents 11,484,531, 12,048,692 and 12,285,417; parties include Theravance subsidiaries and Mylan.

## SEC filing metadata
- accession: 0001104659-26-036870
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465926036870/0001104659-26-036870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465926036870/tm2610626d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-036870
- JSON: https://secwatch.observer/filing/0001104659-26-036870.json
- Plain text: https://secwatch.observer/filing/0001104659-26-036870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.